DM1 with a reactive linker SMCC, which can react with antibody to make antibody drug conjugate, as a potent EGFR inhibitor and it overcomes resistant to EGFR.
Structure of 1228105-51-8
* For research and manufacturing use only. We do not sell to patients.
Size | Price | Stock | Quantity |
---|---|---|---|
10 mg | $298 | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
DM1-SMCC, a potent cytotoxic agent, plays a vital role in the development of antibody-drug conjugates (ADCs) for targeted cancer therapy. Here are four key applications of DM1-SMCC:
Cancer Treatment: At the forefront of targeted cancer therapy, DM1-SMCC is a cornerstone in ADCs engineered to specifically seek out cancer cells. By binding to antibodies that recognize tumor-associated antigens, this cytotoxic agent is delivered directly to malignant cells, minimizing harm to healthy tissues. This precision targeting not only enhances treatment effectiveness but also reduces systemic side effects, heralding a paradigm shift in cancer care.
Pharmacokinetics Studies: In the realm of pharmacokinetics research, DM1-SMCC is a crucial tool for unraveling the behavior and distribution of ADCs in both preclinical and clinical settings. Understanding the journey of these conjugates in the body—from absorption to elimination—is paramount for optimizing dosing strategies and improving therapeutic results. These studies are instrumental in predicting clinical responses and potential adverse reactions.
Drug Development: Serving as a prototypical payload, DM1-SMCC plays a pivotal role in designing the next generation of ADCs. By manipulating linker chemistry or pairing with diverse monoclonal antibodies, scientists can craft innovative ADCs with enhanced stability, potency, and selectivity. This adaptability is key to tailoring treatments for a spectrum of cancer types.
Mechanism of Action Studies: Delving into the intricate mechanisms of ADCs’ cytotoxic effects on cancer cells, DM1-SMCC empowers researchers to explore cellular uptake, intracellular trafficking, and release within targeted cells. These investigations offer profound insights into how ADCs induce cell death, shedding light on resistance mechanisms and optimizing therapeutic approaches. This deep understanding is pivotal for refining cancer treatment strategies and overcoming therapeutic challenges.
Catalog | Product Name | CAS | Inquiry |
---|---|---|---|
BADC-01450 | MCC-DM1 | 1100692-14-5 | |
BADC-00574 | Lys-SMCC-DM1 | 1281816-04-3 | |
BADC-00848 | MC-DM1 | 1375089-56-7 | |
BADC-00020 | DM1-SMe | 138148-68-2 | |
BADC-00601 | Mal-VC-PAB-DM1 | 1464051-44-2 | |
BADC-00668 | SC-VC-PAB-DM1 | 2259318-47-1 | |
BADC-00010 | DM1-SPP | 452072-20-7 | |
BADC-01378 | S-methyl DM1 | 912569-84-7 | |
BADC-01407 | SPDB-DM1 | ||
BADC-01411 | MPB-VC-PAB-DM1 |
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.